Navigation Links
Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
Date:11/5/2012

WASHINGTON, Nov. 5, 2012 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the Lazard Healthcare Conference in New York City on Wednesday, November 14, 2012 at 3:00 p.m. Eastern Time.

The presentation at the Lazard Healthcare Conference will be webcast live on Vanda's corporate website, where it also will be archived for 30 days.  To access the presentation, go to Vanda's website at http://www.vandapharma.com and click on the Presentations tab on the Investor Relations page.  Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... 2020 , ... Diversified Technologies, Inc. has introduced a full ... drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter Systems ... push-pull configuration; yielding fast fall time for a capacitive load. These all solid-state ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... firm for the life sciences and food industries, is pleased to announce that ... Clinical Research – Business Development. , Charles is an accomplished and results-driven sales ...
(Date:7/7/2020)... ... 06, 2020 , ... R3 International is now offering stem cell therapy for ... cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with ... form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. ...
Breaking Biology Technology:
(Date:8/21/2020)... , ... August 18, 2020 , ... ... cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ... lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 11, 2020 , ... ... R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey ... and development. Both Roche and J&J have annual Research and Development spending ...
(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
Breaking Biology News(10 mins):